Reporting from ELCC 2019 in Geneva, D. de Ruysscher explains that the addition of durvalumab to standard therapy has significantly improved the outcome of patients with unresectable stage III Non-Small Cell Lung Cancer. He calls for its integration into the management plan through the multidisciplinary board.
Studies:
- LBA2: Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, Stage III NSCLC (PACIFIC)– (Marina Garassino)
- ID4: My patient needs chemoradiotherapy and durvalumab – (De Ruysscher D.)